Market open
Coherus BioSciences/$CHRS
Coherus BioSciences shares are trading lower after the company reported Q1 results with a loss larger than revenue estimates.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus BioSciences
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.
Ticker
$CHRS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
228
ISIN
US19249H1032
Website
CHRS Metrics
BasicAdvanced
$92M
-
-$1.14
1.01
-
Price and volume
Market cap
$92M
Beta
1.01
52-week high
$2.23
52-week low
$0.66
Average daily volume
1.9M
Financial strength
Current ratio
1.943
Quick ratio
0.98
Long term debt to equity
-144.629
Total debt to equity
-144.629
Interest coverage (TTM)
-3.01%
Management effectiveness
Return on assets (TTM)
-9.10%
Return on equity (TTM)
-37.05%
Valuation
Price to revenue (TTM)
0.335
Price to book
-0.5
Price to tangible book (TTM)
-0.39
Price to free cash flow (TTM)
-3.719
Growth
Revenue change (TTM)
19.87%
Earnings per share change (TTM)
96.34%
3-year revenue growth (CAGR)
-3.57%
3-year earnings per share growth (CAGR)
-25.55%
What the Analysts think about CHRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Coherus BioSciences stock.
CHRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CHRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CHRS News
AllArticlesVideos
Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript
Seeking Alpha·3 days ago
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·3 days ago
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $92M as of May 15, 2025.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0 as of May 15, 2025.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.